المؤلفون: Kandukoori, Naga Raju¹, Yellu, Narsimha Reddy^{2, 1}

المصدر: Research Journal of Pharmacy and Technology 16(3):991-996. 2023

المؤلفون: Gayan Premaratne, Jinesh Niroula, James T. Moulton, Sadagopan Krishnan

مصطلحات موضوعية: Biochemistry, Microbiology, Pharmacology, Biotechnology, Plant Biology, Space Science, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, underlying electrode surface, electrode array configurations, absorbed onto 1, 4 ′- hydroxydiclofenac, recombinant p450 2c9, nonenzymatic metabolite production, metabolizing cytochrome p450, modified graphite electrodes, indicated good stability, cytochrome p450 bactosomes, bactosomal biofilm electrodes, designed microsomal bioelectrode, designed liver microsomal, modified electrodes, designed microsomal, unmodified electrodes, expressed bactosomes, designed biofilms, bactosomal film, throughput potential, single isoform, similar enhancements

Relation: https://figshare.com/articles/journal_contribution/Nanobioelectrocatalysis_Using_Human_Liver_Microsomes_and_Cytochrome_P450_Bactosomes_Pyrenyl-Nanocarbon_Electrodes/25331984

الاتاحة: https://doi.org/10.1021/acsabm.3c01170.s001
https://figshare.com/articles/journal_contribution/Nanobioelectrocatalysis_Using_Human_Liver_Microsomes_and_Cytochrome_P450_Bactosomes_Pyrenyl-Nanocarbon_Electrodes/25331984

المؤلفون: Hany A Al-Hussaniy, Alaa F Hassan, Amjad I Oraibi, Atheer M R. Al-Juhaishi, Fatima A Naji, Zahraa S Al-Tameemi

المصدر: Journal of Pharmacy and Bioallied Sciences, Vol 15, Iss 3, Pp 101-106 (2023)

مصطلحات موضوعية: angiotensin receptor blocker, cytochrome p450 2c9, genetic polymorphism, renin-angiotensin-aldosterone system, Pharmacy and materia medica, RS1-441, Analytical chemistry, QD71-142

وصف الملف: electronic resource

Relation: http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2023;volume=15;issue=3;spage=101;epage=106;aulast=Al-Hussaniy; https://doaj.org/toc/0975-7406

URL الوصول: https://doaj.org/article/95d18a3c5fd94d88a71121074dcda94d

المؤلفون: Leyanis Rodriguez-Vera, Xuefen Yin, Mohammed Almoslem, Karolin Romahn, Brian Cicali, Viera Lukacova, Rodrigo Cristofoletti, Stephan Schmidt

المصدر: Pharmaceutics, Vol 15, Iss 2486, p 2486 (2023)

مصطلحات موضوعية: physiologically based pharmacokinetic modelling (PBPK), drug–drug interactions (DDIs), phenytoin, cytochrome P450 2C9 (CYP2C9), cytochrome P450 2C19 (CYP2C19), Pharmacy and materia medica, RS1-441

Relation: https://www.mdpi.com/1999-4923/15/10/2486; https://doaj.org/toc/1999-4923; https://doaj.org/article/a264f6e2b35344d99f434b3337e22602

الاتاحة: https://doi.org/10.3390/pharmaceutics15102486
https://doaj.org/article/a264f6e2b35344d99f434b3337e22602

المؤلفون: Kaur, Amanpreet, Dreyer, Rachel P, Marsh, Thomas W, Thanassoulis, George, Raparelli, Valeria, D'Onofrio, Gail, Engert, James C, Pilote, Louise

المساهمون: Kaur, Amanpreet, Dreyer, Rachel P, Marsh, Thomas W, Thanassoulis, George, Raparelli, Valeria, D'Onofrio, Gail, Engert, James C, Pilote, Louise

مصطلحات موضوعية: clopidogrel, cytochrome P450, cytochrome P450 2C19, cytochrome P450 2C9, cytochrome P450 3A5

وصف الملف: STAMPA

Relation: info:eu-repo/semantics/altIdentifier/pmid/36444366; info:eu-repo/semantics/altIdentifier/wos/WOS:001085838400003; volume:4; issue:11; firstpage:970; lastpage:978; numberofpages:9; journal:CJC OPEN; https://hdl.handle.net/11392/2499558; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85140307869; https://www.cjcopen.ca/article/S2589-790X(22)00154-8/fulltext

الاتاحة: https://hdl.handle.net/11392/2499558
https://doi.org/10.1016/j.cjco.2022.07.013
https://www.cjcopen.ca/article/S2589-790X(22)00154-8/fulltext

المؤلفون: Anastassia Rudik, Alexander Dmitriev, Alexey Lagunin, Dmitry Filimonov, Vladimir Poroikov

المصدر: Molecules; Volume 27; Issue 18; Pages: 5875

مصطلحات موضوعية: CYP, inhibitors, inducers, (Q)SAR models, PASS, GUSAR, drug-like compounds, metabolism, in silico prediction, P450 isoforms, 1A2, 3A4, 2D6, 2C9, 2C19

جغرافية الموضوع: agris

وصف الملف: application/pdf

Relation: Medicinal Chemistry; https://dx.doi.org/10.3390/molecules27185875

الاتاحة: https://doi.org/10.3390/molecules27185875

المؤلفون: Victoria V. Shumyantseva, Tatiana V. Bulko, Polina I. Koroleva, Evgeniya V. Shikh, Anna A. Makhova, Maryia S. Kisel, Irina V. Haidukevich, Andrei A. Gilep

المصدر: Processes, Vol 10, Iss 383, p 383 (2022)

مصطلحات موضوعية: cytochrome P450 2C9, diclofenac, electrochemical analysis, polymorphism, taurine, mexidol, Chemical technology, TP1-1185, Chemistry, QD1-999

Relation: https://www.mdpi.com/2227-9717/10/2/383; https://doaj.org/toc/2227-9717; https://doaj.org/article/72702f4190dc431594be37bd03534ce4

الاتاحة: https://doi.org/10.3390/pr10020383
https://doaj.org/article/72702f4190dc431594be37bd03534ce4

المؤلفون: K. M. Muratov, I. V. Stuk, N. I. Lapudus, К. М. Муратов, И. В. Стук, Н. И. Лапидус

المصدر: Pharmacogenetics and Pharmacogenomics; № 1 (2021); 24-32 ; Фармакогенетика и фармакогеномика; № 1 (2021); 24-32 ; 2588-0527 ; 2686-8849

مصطلحات موضوعية: полиморфизм CYP 2C9, arterial hypertension, comorbidity, polymorphism CYP 2C9, артериальная гипертензия, коморбидность

وصف الملف: application/pdf

Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/215/212; World Health Organization. Guidelines on community-level interventions to manage declines in intrinsic capacity. Geneva: WHO; 2017.; Родионов А.В. Нестероидные противовоспалительные препараты и артериальная гипертензия: актуальность проблемы и тактика ведения пациентов. Лечащий врач. 2013;(2):25; Хуцишвили М.Ш., Батурин В.А. Фармакоэпидемиологическое исследование потребления нестероидных противовоспалительных средств в стационаре до и после внедрения формулярной системы. Саратовский научно-медицинский журнал. 2008;19(1):130–134.; Harley C, Wagner S. The prevalence of cardiovascular risk factors in patients prescribing anti-inflammatory drugs: data from managed care. Clin Ther. 2003;25(1):139–149. DOI:10.1016/s0149-2918(03)90017-890017-8.; Curhan G, Willet W, Rosner B, Stampfer M. Frequency оf analgesic use and risk of hypertension in younger woman. Arch Intern Med. 2002;162(19):2204–2208. DOI:10.1001/archinte.162.19.2204.; Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549); 1771–1781. DOI:10.1016/S0140-6736(06)69666-9.; Майчук Е.Ю., Воеводина И.В. Современные представления об использовании ингибиторов ангиотензинпревращающего фермента для лечения артериальной гипертензии. РМЖ. 2005;13(19):1287–1291.; Бобров В.А., Давыдова И.В., Медведенко О.И. Актуальные вопросы лекарственных взаимодействий в клинической практике. Как выбрать оптимальный ингибитор АПФ для больного, принимающего НПВС? Украинский медицинский журнал. 2010;1(75):43–48.; Котова О.В. Вопросы безопасности применения нестероидных противовоспалительных средств у больных с заболеваниями опорно-двигательного аппарата в сочетании с артериальной гипертензией. Фарматека. 2011;20:63–67.; Галанова А.С., Назирова Ю.Б., Шилов А.М. Ингибиторы ангиотензин-превращающего фермента в кардиологической практике. Акцент на Лизигамму. РМЖ. 2007;15(20):1460–1465.; Theken KN, Lee CR, Gong L. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191–200. DOI:10.1002/cpt.1830.; Каратеев АЕ. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018;12(2):64–72.; Villa J, Cano A, Franco D et al. Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives. Aten Primaria. 2014;46(9):464–474. DOI:10.1016/j.aprim.2013.11.010.; Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44(2):140–145. DOI:10.1161/01.HYP.0000136134.31846.83.; Nissen SE, Yeomans ND, Solomon DH et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26); 2519–2529. DOI:10.1056/NEJMoa1611593.; Chan C, Reid C, Aw Т et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009;27(12):2332–2341. DOI:10.1097/HJH.0b013e3283310dc9.; Dilger K, Herrlinger C, Peters J et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol. 2002;42(9):985–994.; Шостак Н.А., Клименко А.А. Нестероидные противовоспалительные препараты – современные аспекты их применения. Клиницист. 2013;3-4:53-61.; Прохорович Е.А. Нестероидные противовоспалительные препараты – собрание клонов или содружество ярких индивидуальностей? Взгляд клинического фармаколога. РМЖ. 2020;6:2-9.; Rotunno R, Oppo G, Saetta I et al. NSAIDs and heart failure: A dangerous relationship. Monaldi Arch Chest Dis. 2018;88(2):950. DOI:10.4081/monaldi.2018.950.; Li L, Zhou X, Ching WK, Wang P. Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI-60 cell lines. BMC Bioinformatics. 2010;11:501. DOI:10.1186/1471-2105-11-501.; Wang Y, Yi X-D, Lu H-L. Influence of CYP2C9 and COX-2 Genetic Polymorphisms on Clinical Efficacy of Non-Steroidal Anti-Inflammatory Drugs in Treatment of Ankylosing Spondylitis. Med Sci Monit. 2017;23:1775–1782. DOI:10.12659/msm.900271.; Леонова М.В., Алимова Э.Э. Фармакогенетика нестероидных противовоспалительных препаратов: существующие проблемы для клинической практики. Медицинский совет. 2018;21:204-209.; Ingrasciotta Y, Sultana J, Giorgianni F et al. Association of individual nonsteroidal anti-inflammatory drugs and chronic kidney disease: A population-based case control study. PLoS One. 2015;10(4):e0122899. DOI:10.1371/journal.pone.0122899.; Table of Pharmacogenomic Biomarkers in Drug Labels. 2013. [cited 2021 Oct 19];Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ ucm083378.htm; Cornett ЕМ, Turpin MA, Pinner A. Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism. Curr Oncol Rep. 2020;22(2):18. DOI:10.1007/s11912-020-0865-4.; Nandagopal А, Unnisa SV, Shireen B, Tasleem S. Cytochrome Р450 – role in drug metabolism and genetic polymorphism. IAJPS. 2018;05(04):2979–2989. DOI:10.5281/zenodo.1231058; Сычев Д.А., Игнатьев В.И., Раменская Д.В., Кукес В.Г. Клиническая фармакогенетика. – М.: ГЭОТАР-Медиа; 2007. – 248 с.; Коваленко Ф.А., Скибицкий В.В., Фендрикова А.В., Лазарев К.Ю., Луконин И.А. Эффективность комбинированной антигипертензивной терапии у пациентов с артериальной гипертонией и ожирением в зависимости от полиморфизма гена CYP2C9. Кубанский научный медицинский вестник. 2018;25(2):94-100.; Слепухина А.А., Зеленская Е.М., Лифшиц Г.И. Генетические факторы риска сосудистого старения: молекулярные механизмы, полиморфизм генов-кандидатов и генные сети. Российский кардиологический журнал. 2019;24(10):78-85.; Сычёв Д.А., Бордовский С.П., Никулин В.Э., Польшина Н.И., Аникин Г.С., Данилина К.С., Смирнов В.В., Отделенов В.А. Сопоставление активности изофермента цитохрома Р450 CYP2C9 у пациентов пожилого и старческого возраста и у здоровых добровольцев первого периода зрелого возраста. Фармакогенетика и фармакогеномика. 2016;(2):19–23.; Matsui S. Genomic Biomarkers for Personalized Medicine: Development and Validation in Clinical Studies. Comput Math Methods Med. 2013;2013:865980. DOI:10.1155/2013/865980.; Donner KM, Hiltunen TP, Suonsyrjä Т et al. CYP2C9 genotype modifi es activity of the renin-angiotensin-aldosterone system in hypertensive men. J Hypertens. 2009;27(10):2001–2009. DOI:10.1097/HJH.0b013e32832f4fae.; Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797–814. DOI:10.2165/00003088-200544080-00003.; Meadowcroft AM, Williamson KM, Patterson JH et al. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1999;39(4):418–424. DOI:10.1177/00912709922007886.; Williamson KM, Patterson JH, McQueen RH et al. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1998;63(3):316–323. DOI:10.1016/S0009-9236(98)90163-1.; Kazierad DJ, Martin DE, Blum RA et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther. 1997;62(4):417–425. DOI:10.1016/S0009-9236(97)90120-X.; Грибакина О.В., Колыванов Г.Б., Литвин А.А. и др. Фармакокинетические взаимодействия лекарственных веществ, метаболизируемых изоферментом цитохрома P450 CYP2C9. // Фармакокинетика и фармакодинамика. – 2016. - № 1. – С. 21–32.; https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/215

الاتاحة: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/215
https://doi.org/10.37489/2588-0527-2021-1-24-32

المؤلفون: E. V. Shikh, A. A. Makhova, V. V. Shumyantseva, O. A. Demidova

المصدر: Регуляторные исследования и экспертиза лекарственных средств, Vol 0, Iss 4, Pp 42-47 (2018)

مصطلحات موضوعية: цитохром p450 3a4, цитохром p450 2c9, диклофенак, антиоксиданты, электрохимия, ферментные электроды, витамины a, c, e, витамины группы b, взаимодействие, cytochrome p450 2c9, cytochrome p450 3a4, diclofenac, antioxidants, electrochemistry, enzyme electrodes, a, c, e vitamins, b vitamins, interaction, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: https://www.vedomostincesmp.ru/jour/article/view/105; https://doaj.org/toc/3034-3062; https://doaj.org/toc/3034-3453

URL الوصول: https://doaj.org/article/1e454c64746e4aaf9753105dc5bca37f

المؤلفون: I. I. Sinitsina, A. V. Boyarko, I. I. Temirbulatov, И. И. Синицина, А. В. Боярко, И. И. Темирбулатов

المصدر: Pharmacogenetics and Pharmacogenomics; № 1 (2020); 19-25 ; Фармакогенетика и фармакогеномика; № 1 (2020); 19-25 ; 2588-0527 ; 2686-8849

مصطلحات موضوعية: ренин–ангиотензин–альдостероновая система (РААС), genetic polymorphism, cytochrome P450 2C9, renin-angiotensin-aldosterone system (RAAS), генетический полиморфизм, цитохром P450 2C9

وصف الملف: application/pdf

Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/183/183; Ponikowski P, Voors AA, Anker SD, et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016;37:2129-2200m. 10.1093/eurheartj/ehw128; Williams B, Mancia G, Spiering W, et al 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339; Rodgers JE, Patterson JH (2001) Angiotensin II-receptor blockers: Clinical relevance and therapeutic role. Am. J. Heal. Pharm. 2001;58:671–683; Сычев Д.А., Раменская Г.В., Игнатьев И.В., Кукес В.Г. Клиническая фармакогенетика: Учебное пособие / Под ред. В.Г. Кукеса, Н.П. Бочкова.- М.:ГЭОТАР Медиа. 2007. [Sychev D.A., Ramenskaya G.V., Ignat'ev I.V., Kukes V.G. Klinicheskaya farmakogenetika: Uchebnoe posobie / Ed by V.G. Kukes, N.P. Bochkova.- M.:GEOTAR Media. 2007 (In Russ).]; Isvoran A, Louet M, Vladoiu DL, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. 2017;22:366–376. https://doi.org/10.1016/j.drudis.2016.09.015; Spiering W, Kroon AA, Fuss-Lejeune MJMJ, De Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens. 2005;23:753–758. https://doi.org/10.1097/01.hjh.0000163143.66965.06; Wang B, Wang J, Huang S-Q, et al. Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Curr Drug Metab. 2009;10:781–834. https://doi.org/10.2174/138920009789895480; Zhou Y, Ingelman-Sundberg M, Lauschke VM (2017) Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther. 2017;102:688–700. https://doi.org/10.1002/cpt.690; Мирзаев К.Б., Федоринов Д.С., Иващенко Д.В., Сычев Д.А. Мультиэтнический анализ кардиологических фармакогенетических маркеров генов цитохрома Р450 и мембранных транспортеров в российской популяции. Рациональная Фармакотерапия в Кардиологии 2019;15(3):393-406. [Mirzaev K.B., Fedorinov D.S., Ivashchenko D.V., Sychev D.A. Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome p450 and Membrane Transporters Genes in the Russian Population. Rational Pharmacotherapy in Cardiology 2019;15(3):393-406. (In Russ).] DOI:10.20996/1819-6446-2019-15-3-393-406; Карева Е.Н. Эволюция сартанов или все ли сартаны одинаковы? Клин. фармакол. тер., 2016, 25 (3), 11-21. [Kareva E.N. Evolution of angiotensin receptor blockers. Clin. Pharmacol. Ther. 2016;25(3):11-21. (In Russ).]; Redon J, Fabia JM. Efficacy in angiotensin receptor blockade: A comparative review of data with olmesartan. JRAAS - J. Renin-Angiotensin-Aldosterone Syst. 2009;10:147–156; Cabaleiro T, Román M, Ochoa D, et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos. 2013;41:224–229. https://doi.org/10.1124/dmd.112.046292; Sica DA, Gehr TWB, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44:797–814. https://doi.org/10.2165/00003088-200544080-00003; Yasar U, Forslund-Bergengren C, Tybring G, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002;71:89–98. https://doi.org/10.1067/mcp.2002.121216; Babaoglu MO, Yasar U, Sandberg M, et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol. 2004;60:337–342. https://doi.org/10.1007/s00228-004-0785-5; Allabi AC, Gala JL, Horsmans Y, et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin Pharmacol Ther. 2004;76:113–118. https://doi.org/10.1016/j.clpt.2004.04.001; Lee CR, Pieper JA, Hinderliter AL, et al. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy. 2003;23:720–725. https://doi.org/10.1592/phco.23.6.720.32187; Леонова М.В. Сартаны в лечении артериальной гипертонии: преимущества кандесартана. Consilium Medicum. 2019;21(1):25–30. [Leonova M.V. Sartany v lechenii arterial'noi gipertonii: preimushchestva kandesartana. Consilium Medicum. 2019;21(1):25–30. (in Russ.)] DOI:10.26442/20751753.2019.1.190280; Hallberg P, Karlsson J, Kurland L, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens. 2002;20:2089–2093. https://doi.org/10.1097/00004872-200210000-00030; Hong X, Zhang S, Mao G, et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol. 2005;61:627–634. https://doi.org/10.1007/s00228-005-0976-8; Hanatani T. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J. 2001;1:288–292. https://doi.org/10.1038/sj.tpj.6500063; Procopciuc L, Popescu T, Jebeleanu G, et al. Essential arterial hypertension and polymorphism of angiotensinogen M235T gene. J Cell Mol Med. 2002;6:245–250. https://doi.org/10.1111/j.1582-4934.2002.tb00191.x; Zhou A, Carrell RW, Murphy MP, et al. A redox switch in angiotensinogen modulates angiotensin release. Nature. 2010;468:108–111. https://doi.org/10.1038/nature09505; Муженя Д.В. Патофизиологическая роль и прогностическая значимость М235Т полиморфизма гена ангиотензиногена (AGТ) при болезнях сердечного континуума (БСК) // Вестн. Адыгейского гос. ун-та. Сер. 4: Естеств.-матем. и техн. науки. 2011. № 3. С. 69–81. [Pathophysiological role and the prognostic importance of the angiotensinogen (AGT) gene M235T polymorphism at illnesses of a heart continuum. Vestnik Adygeiskogo gosudarstvennogo universiteta, seriya «Estestvenno-matematicheskie i tekhnicheskie nauki 2011;(3):69–81. (in Russ.)]; Страмбовская Н.Н. Прогностическая роль полиморфных вариантов генов-кандидатов у больны ишемическим инсультом в Забайкалье // Фундам. исследования. 2015. № 1. С. 140–144. [Strambovskaya N.N Рrognostic role genetic polymorphisms for ischemic stroke patients in transbaikal region. 2015;(1):140-144.(in Russ.)]; Watkins WS, Hunt SC, Williams GH, et al. Genotype-phenotype analysis of angiotensinogen polymorphisms and essential hypertension: The importance of haplotypes. J Hypertens. 2010;28:65–75. https://doi.org/10.1097/HJH.0b013e328332031a; Зотова Т.Ю., Кубанова А.П., Азова М.М., Аит Аисса Амира. Особенности клинического течения артериальной гипертензии в зависимости от полиморфного варианта гена AGTR1. Клин. мед. 2017; 95(5):404-407. [Zotova T.Yu., Kubanova A.P., Azova M.M., Aut Aissa Amira Peculiarities of the clinical picture of arterial hypertension depending on polymorphic variant of AGTR1 gene. Klin. med. 2017;95(5):404-407. DOI http://dx.doi.org/10.18821/0023-2149-2017-95-5-404-407(in Russ.)]; Redon J, Luque-Otero M, Martell N, et al. Renin-angiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J. 2005;5:14–20. https://doi.org/10.1038/sj.tpj.6500280; Van De Wal RMA, Van Veldhuisen DJ, Van Gilst WH, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: Controversial or common sense? Eur. Heart J. 2005;26:2361–2367; Zhang H, Sun M, Sun T, et al. Association between angiotensin II type 1 receptor gene polymorphisms and ischemic stroke: A meta-analysis. Cerebrovasc Dis. 2011;32:431–438. https://doi.org/10.1159/000330655; Szolnoki Z, Havasi V, Talián G, et al. Angiotensin II type-1 receptor A1166C polymorphism is associated with increased risk of ischemic stroke in hypertensive smokers. J Mol Neurosci. 2006;28:285–290. https://doi.org/10.1385/JMN:28:3:285; Rubattu S, Di Angelantonio E, Stanzione R, et al. Gene polymorphisms of the renin-angiotensin-aldosterone system and the risk of ischemic stroke: A role of the A1166C/AT1 gene variant. J Hypertens. 2004;22:2129–2134. https://doi.org/10.1097/00004872-200411000-00015; Weekers L, Bonhanick B, Hadjadj S, et al. Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes. 2005;54:2961–2967. https://doi.org/10.2337/diabetes.54.10.2961; Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005;111:3374–3383. https://doi.org/10.1161/CIRCULATIONAHA.104.504639; Kurland L, Melhus H, Karlsson J, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens. 2002;20:657–663. https://doi.org/10.1097/00004872-200204000-00023; Conrady AO, Kiselev IO, Usachev NI, et al. (2005) Effect of 24-week treatment with telmisartan on myocardial structure and function: Relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene. J Int Med Res. 2005;33 Suppl 1:30A-38A. https://doi.org/10.1177/14732300050330s105; Jia M, Yang B, Li Z, et al. Computational analysis of functional single nucleotide polymorphisms associated with the CYP11B2 gene. PLoS One. 2014; 7;9(8):e104311. https://doi.org/10.1371/journal.pone.0104311; Heller S, Linhart A, Jindra A, et al. Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. Blood Press. 2004;13:158–163. https://doi.org/10.1080/08037050410035554; Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol. 2002;445:151–152. https://doi.org/10.1016/S0014-2999(02)01766-1; Wang L, Zhang Z, Liu D, et al (2020) Association of −344C/T polymorphism in the aldosterone synthase (CYP11B2) gene with cardiac and cerebrovascular events in Chinese patients with hypertension. J Int Med Res. 2020;48(9):300060520949409. https://doi.org/10.1177/0300060520949409; Pi Y, Zhang L li, Chang K, et al. Lack of an Association between CYP11B2 C-344T Gene Polymorphism and Ischemic Stroke: A Meta-Analysis of 7,710 Subjects. PLoS One. 2013;8(8):e68842. https://doi.org/10.1371/journal.pone.0068842; Androulakis E, Tousoulis D, Miliou A, et al. The impact of an aldosterone synthase (CYP11B2) polymorphism on vascular function and inflammatory biomarkers in essential hypertension. J Am Coll Cardiol. 2012;59:E1634. https://doi.org/10.1016/s0735-1097(12)61635-0; Chandra S, Saluja D, Narang R, et al. Atrial natriuretic peptide and aldosterone synthase gene in essential hypertension: A case-control study. Gene. 2015;567:92–97. https://doi.org/10.1016/j.gene.2015.04.062; Byrd JB, Auchus RJ, White PC (2015) Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study. J Investig Med. 2015;63:862–866. https://doi.org/10.1097/JIM.0000000000000220; https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/183

الاتاحة: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/183
https://doi.org/10.37489/2588-0527-2020-1-19-25

المؤلفون: Xiao-Yang Zhou, Xiang-Ran Lu, Ying-Hui Li, Ya-Qing Ma, Shi-Wen Zhao, Fang Wang, Ren-Ai Xu, Guo-Xin Hu, Jian-Ping Cai

المصدر: Frontiers in Pharmacology, Vol 12 (2021)

مصطلحات موضوعية: cytochrome P450 2C9, allelic variant, drug metabolism, enzymatic activity evaluation in vitro, tolbutamide, losartan, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2021.619339/full; https://doaj.org/toc/1663-9812

URL الوصول: https://doaj.org/article/1c8e15da34954718b93406f2728abe26

المؤلفون: Myung, Sun Jung, Yoon, Jung-Hwan, Yu, Su Jong

المساهمون: Myung, Sun Jung, Yoon, Jung-Hwan

مصطلحات موضوعية: HEPATOCELLULAR-CARCINOMA, THERAPEUTIC IMPLICATIONS, SIDE POPULATION, GROWTH, EPIDEMIOLOGY, ANGIOGENESIS, PHENOTYPE, PROMOTES, 2J2, Cancer stem cell, Cytochrome P450 epoxygenase 2C9, inhibitor, STAT3, Hypoxia

Relation: Biomedicine and Pharmacotherapy, Vol.66 No.8, pp.612-616; https://hdl.handle.net/10371/203902; 000313513200008; 2-s2.0-84869862953; 144143

الاتاحة: https://hdl.handle.net/10371/203902
https://doi.org/10.1016/j.biopha.2012.08.011

المؤلفون: Alexander V. Dmitriev, Anastassia V. Rudik, Dmitry A. Karasev, Pavel V. Pogodin, Alexey A. Lagunin, Dmitry A. Filimonov, Vladimir V. Poroikov

المصدر: Pharmaceutics; Volume 13; Issue 4; Pages: 538

مصطلحات موضوعية: drug interaction, DDI, computational prediction, in silico, QSAR, drug metabolism, ADME, pharmacokinetics, CYP, polypharmacy, metabolic DDI, P450, 1A2, 2B6, 2C19, 2C8, 2C9, 2D6, 3A4

وصف الملف: application/pdf

Relation: Pharmacokinetics and Pharmacodynamics; https://dx.doi.org/10.3390/pharmaceutics13040538

الاتاحة: https://doi.org/10.3390/pharmaceutics13040538

المؤلفون: Masaki Kumondai, Akio Ito, Evelyn Marie Gutiérrez Rico, Eiji Hishinuma, Akiko Ueda, Sakae Saito, Tomoki Nakayoshi, Akifumi Oda, Shu Tadaka, Kengo Kinoshita, Masamitsu Maekawa, Nariyasu Mano, Noriyasu Hirasawa, Masahiro Hiratsuka

المصدر: Journal of Personalized Medicine; Volume 11; Issue 2; Pages: 94

مصطلحات موضوعية: cytochrome P450 2C9, genetic variation, ( S )-warfarin, tolbutamide, drug metabolism

وصف الملف: application/pdf

Relation: Omics/Informatics; https://dx.doi.org/10.3390/jpm11020094

الاتاحة: https://doi.org/10.3390/jpm11020094

المؤلفون: Zahi Abu Ghosh, Shoshana Alamia, Chanan Shaul, Yoseph Caraco

المصدر: Frontiers in Pharmacology, Vol 11 (2020)

مصطلحات موضوعية: CYP2C9, cytochrome P450 complex subunit 2C9, phenytoin, in vivo activity, ethnicity, genetic polymorphism, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fphar.2020.566842/full; https://doaj.org/toc/1663-9812

URL الوصول: https://doaj.org/article/284878a50d6347cd98961944e41a45af

المؤلفون: Hossam Y.K Mohammed, Yousry Z Al-Zohairy, Mahmoud Abd El-Latif Hashish

المصدر: Al-Azhar Assiut Medical Journal, Vol 16, Iss 4, Pp 371-376 (2018)

مصطلحات موضوعية: cytochrome p-450 2c9 enzyme, pcr, vitamin k epoxide reductase complex 1, warfarin (marevan) oral anticoagulant, Internal medicine, RC31-1245

وصف الملف: electronic resource

Relation: http://www.azmj.eg.net/article.asp?issn=1687-1693;year=2018;volume=16;issue=4;spage=371;epage=376;aulast=Mohammed; https://doaj.org/toc/1687-1693

URL الوصول: https://doaj.org/article/3119e938431f4e7c829bda338aba6a2f

المؤلفون: Fakih, Taufik Muhammad, Dewi, Mentari Luthfika

المصدر: Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal); Vol. 6 No. 2 (2020): (October 2020) ; 2442-8744 ; 2442-7284 ; 10.22487/j24428744.2020.v6.i2

مصطلحات موضوعية: Anticoagulant, Cytochrome P450 (CYP) 2C9, Marine Bioactive Peptides, Protein-Peptide Docking, In silico Study

وصف الملف: application/pdf

Relation: https://bestjournal.untad.ac.id/index.php/Galenika/article/view/15041/11393; https://bestjournal.untad.ac.id/index.php/Galenika/article/view/15041

الاتاحة: https://bestjournal.untad.ac.id/index.php/Galenika/article/view/15041
https://doi.org/10.22487/j24428744.2020.v6.i2.15041

المؤلفون: Rojo, M., Roco, A., Suarez, M., Lavanderos, M., Verón, G., Bertoglia, M., Arredondo, A., Nieto, E., Rubilar, J., Tamayo, F., Cruz, D., Muñoz, J.

مصطلحات موضوعية: acenocoumarol, coumarin, pharmacogenetics, polymorphisms, VKA, Cytochrome P450 2C9, Warfarin, Vitamin K Epoxide Reductase

وصف الملف: application/pdf

Relation: Clinical and Applied Thrombosis/Hemostasis, Volume 26, 2020; http://repositorio.unab.cl/xmlui/handle/ria/20346

الاتاحة: http://repositorio.unab.cl/xmlui/handle/ria/20346
https://doi.org/10.1177/1076029620909154

المؤلفون: Hayran, Yildiz, Allı, Nuran, Uysal, Pınar İncel, Çandar, Tuba

مصطلحات موضوعية: Disease susceptibility, Psoriasis, Polymorphism, Single nucleotide, Soluble epoxide hydrolase, Coronary-heart-disease, Genetic-variation, Cytochrome-P450, Risk, Prevalence, 2J2, Card14, G-50T, 2C9

وصف الملف: application/pdf

Relation: Anais Brasileiros De Dermatologia; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Hayran, Y., Alli, N., Uysal, P. I., & Candar, T. (2020). Association of CYP2J2 polymorphism with susceptibility to psoriasis in Turkish population: a case–control study. Anais Brasileiros de Dermatologia, 95(1), 25–31. https://doi.org/10.1016/j.abd.2019.04.006; https://doi.org/10.1016/j.abd.2019.04.006; https://hdl.handle.net/20.500.14065/2776; 95; 25; 31; Q3; WOS:000518857800004; 2-s2.0-85077304932

الاتاحة: https://doi.org/10.1016/j.abd.2019.04.006
https://hdl.handle.net/20.500.14065/2776

المؤلفون: A O Rubanenko, Yu V Shchukin

المصدر: Наука и инновации в медицине, Vol 1, Iss 4, Pp 18-22 (2016)

مصطلحات موضوعية: atrial fibrillation, genetic polymorphisms, cytochrome p450 2c9, vitamin k epoxide-reductase subunit 1, warfarin, Medicine

وصف الملف: electronic resource

Relation: https://innoscience.ru/2500-1388/article/viewFile/21524/17764; https://doaj.org/toc/2500-1388; https://doaj.org/toc/2618-754X

URL الوصول: https://doaj.org/article/b32be50b762a4c658a45805a492961f6